Recent data shows that the combination therapy of TG-101348 and BI-2536 (PLK1 inhibitors) synergistically targets oncogenic pathways [38] and that the combination therapy of TG101348 and imatinib (ABL kinase inhibitor) inhibits cell proliferation of BCR-ABL-positive chronic myeloid leukemia cells [40]. This evidence concerns the gene PLK1 and chronic myelogenous leukemia, BCR-ABL1 positive.